Monitoring therapeutic monoclonal antibodies in brain tumor

Bevacizumab induces normalization of abnormal blood vessels, making them less leaky. By binding to vascular endothelial growth factor, it indirectly attacks the vascular tumor mass. The optimal delivery of targeted therapies including monoclonal antibodies or anti-angiogenesis drugs to the target ti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:MAbs
Autores principales: Ait-Belkacem, Rima, Berenguer, Caroline, Villard, Claude, Ouafik, L’Houcine, Figarella-Branger, Dominique, Beck, Alain, Chinot, Olivier, Lafitte, Daniel
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2014
Materias:
Short Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622724/
https://ncbi.nlm.nih.gov/pubmed/25484065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.34405
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares